Somatotropin
Also known as: Genotropin, HGH, Human Growth Hormone, Humatrope, Norditropin, rhGH, Saizen, Somatropin
Source Somatotropin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Somatotropin, also known as human growth hormone (HGH), is a peptide hormone produced by the anterior pituitary that promotes growth and metabolic activity. It is available by prescription in injectable forms and is used in clinical settings under regulated conditions. In agriculture, recombinant bovine somatotropin has been employed to increase milk production in dairy cows.
Mechanism of Action
Somatotropin secretion is stimulated by hypothalamic growth‑hormone‑releasing hormone (GHRH) and inhibited by somatostatin acting on pituitary somatotropes. Once released, somatotropin binds to growth‑hormone receptors on target tissues, initiating intracellular signalling cascades that drive protein synthesis, lipolysis, and glucose metabolism, ultimately supporting linear growth and tissue development.
What the Research Shows
One review highlighted GHRH as an experimental means to boost endogenous somatotropin in children with growth deficiency, noting encouraging early results but emphasizing that therapy remains investigational. In dairy science, a study of recombinant bovine somatotropin reported up to a 40% rise in milk yield with daily injections, with cows adjusting feed intake to meet metabolic demands and no overt health problems observed during lactations shorter than one full cycle. Safety assessments for the consumer and the animal were discussed, though long‑term data were lacking.
Reported Benefits
In cattle, somatotropin administration can markedly increase milk output without immediate adverse effects, potentially improving farm productivity. Experimental use of GHRH to raise endogenous somatotropin suggests a possible route to accelerate growth in GH‑deficient children, though this benefit is based on early, limited investigations.
Limitations of the Evidence
Human clinical evidence for somatotropin‑based growth promotion is not presented in the cited literature; GHRH therapy remains experimental. Dairy studies were limited to periods shorter than a full lactation, leaving long‑term health and reproductive impacts uncertain. Safety data for consumers of milk from treated cows are mentioned but not quantified, highlighting a gap in comprehensive risk assessment.
Safety Considerations
Short‑term bovine studies reported no adverse health effects in treated cows, and preliminary safety evaluations concluded no obvious risk to consumers, though detailed outcomes were not provided. In humans, the abstracts do not address somatotropin safety, and the experimental nature of GHRH therapy implies that safety profiles are still being defined.
How It Is Administered
Somatotropin is supplied as a sterile injectable solution and may be administered intramuscularly, intravenously, or subcutaneously, depending on the formulation and clinical protocol.
Routes of Administration
Goals & Uses
- Treatment of growth hormone deficiency (adult)Endocrinology / MetabolismHigh
- HIV‑associated wastingIndicationModerate
- Anti-aging / performance enhancementOff Label / IllicitLow
- Growth hormone deficiency (adult)IndicationHigh
- Short bowel syndromeGastroenterologyModerate
- Prader‑Willi syndromeIndicationModerate
- Short stature associated with Turner syndrome, Prader-Willi syndrome, or SGAPediatric EndocrinologyHigh
- HIV-associated wasting / cachexiaInfectious Disease / MetabolismHigh
- Turner syndromeIndicationModerate
- Chronic kidney disease (pediatric)IndicationModerate
- Growth hormone deficiency (pediatric)IndicationHigh
- Treatment of growth hormone deficiency (pediatric)Endocrinology / PediatricsHigh
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- Closed epiphyses (for growth promotion indication)Pediatric / SkeletalModerate
- AcromegalyEndocrineHigh
- Acute critical illness (post-surgery, trauma, respiratory failure)Critical CareHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Diabetic retinopathyOphthalmologyModerate
- Uncontrolled Diabetes MellitusMetabolic / EndocrineModerate
- Active proliferative or severe non-proliferative diabetic retinopathyOphthalmologyHigh
- Severe acute critical illnessCritical CareModerate
- Prader-Willi syndrome with severe obesity or respiratory impairmentGenetic SyndromeHigh
- Hypersensitivity to somatropin or excipientsAllergy / ImmunologyHigh
Adverse Effects
- Joint painMusculoskeletalCommonPain in one or more joints
- EdemaFluid BalanceCommonSwelling from fluid retention
- Insulin resistance / hyperglycemiaMetabolicUncommon
- Fluid retention / peripheral edemaCardiovascularCommon
- Injection site reactionsLocalCommon
- Carpal tunnel syndromeMusculoskeletalUncommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Intracranial hypertensionNeurologicalRare
- Hyperglycemia / insulin resistanceMetabolic / EndocrineUncommon
- Intracranial hypertension (pseudotumor cerebri)NeurologicalRare
- Slipped capital femoral epiphysisMusculoskeletalRare
- Arthralgia and myalgiaMusculoskeletalCommon
Drug Interactions
- Insulin and oral antidiabetic agentsModerate
- InsulinModerateMay increase risk of low blood sugar
- GlucocorticoidsModerate
- Thyroid hormonesModerate
- Cytochrome P450-metabolized drugs (e.g., cyclosporine, sex steroids, anticonvulsants)Low
- Estrogen (oral)Moderate
- Cytochrome P450 inducersLow
- Oral estrogenModerate
- somatostatin analogsLow
Population Constraints
- Patients with active infectionInfectiousRelative
- PregnancyReproductive SafetyRelative
- Elderly (>65 years)AgeRelative
- History of malignancyOncologyRelative
- Diabetes mellitusMetabolicRelative
- Adults with GH deficiencyAdultRelative
- Pregnant or lactating womenReproductiveRelative
- Patients with severe renal impairmentOrgan ImpairmentRelative
- NeonatesPediatricRelative
- Children with open epiphysesPediatricAbsolute
- Hypothyroidism (untreated)EndocrineRelative
Regulatory Status
- European UnionApprovedApproved: Growth hormone deficiency (pediatric), Growth hormone deficiency (adult), Turner syndrome, Prader-Willi syndrome, Chronic kidney diseaseEMA approval for multiple recombinant GH formulations.
- United StatesApprovedApproved: Growth hormone deficiency (pediatric), Growth hormone deficiency (adult), Turner syndrome, Prader-Willi syndrome, Chronic kidney disease (pediatric), HIV-associated wastingFDA approved recombinant hGH products (e.g., Genotropin, Norditropin).
- United KingdomApprovedApproved: Growth hormone deficiency (pediatric), Growth hormone deficiency (adult), Turner syndromeMHRA-approved GH products.
FDA‑approved for pediatric growth failure, adult GH deficiency, Turner syndrome, Prader‑Willi syndrome, chronic kidney disease, and HIV‑associated wasting.
Evidence & Sources
- Journal ArticleModerateVance ML1990-01-01T00:00:00.000000Z
- Journal ArticleModerateLeung K2004-01-01T00:00:00.000000Z
- Journal ArticleModeratePeel CJ, Bauman DE1987-01-01T00:00:00.000000Z
Frequently Asked Questions
What is somatotropin used for in humans?
The cited literature does not describe approved human indications; it notes that experimental use of GHRH to raise endogenous somatotropin has been explored for growth‑deficient children, but this approach remains investigational.
How does somatotropin increase milk production in cows?
Daily injections of recombinant bovine somatotropin stimulate metabolic pathways that enhance synthesis of lactose, fat, and protein in the mammary gland, leading to up to a 40% increase in milk yield while cows increase feed intake to meet the higher demand.
Are there any known safety concerns with somatotropin use?
Short‑term studies in dairy cows reported no adverse health effects, and early safety evaluations suggested no immediate risk to consumers, but long‑term effects on animal health and human consumers have not been fully characterized.
What routes can somatotropin be given by?
Somatotropin is formulated for injection and may be delivered intramuscularly, intravenously, or subcutaneously.
Is somatotropin approved for any medical conditions?
The structured data indicates it is an approved prescription product, but the provided abstracts do not specify the medical conditions for which it has regulatory approval.
What is Somatotropin used for?
Somatotropin is educationally associated with: Treatment of growth hormone deficiency (adult), HIV‑associated wasting, Anti-aging / performance enhancement, Growth hormone deficiency (adult), Short bowel syndrome, Prader‑Willi syndrome, Short stature associated with Turner syndrome, Prader-Willi syndrome, or SGA, HIV-associated wasting / cachexia, Turner syndrome, Chronic kidney disease (pediatric), Growth hormone deficiency (pediatric), Treatment of growth hormone deficiency (pediatric). Educational only — not medical advice.
How is Somatotropin administered?
Recorded routes of administration: Intramuscular, Intravenous, Subcutaneous.
What are the potential side effects of Somatotropin?
Reported adverse effects include: Joint pain, Edema, Insulin resistance / hyperglycemia, Fluid retention / peripheral edema, Injection site reactions, Carpal tunnel syndrome, Headache, Intracranial hypertension, Hyperglycemia / insulin resistance, Intracranial hypertension (pseudotumor cerebri), Slipped capital femoral epiphysis, Arthralgia and myalgia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Somatotropin?
Recorded contraindications: Active malignancy, Closed epiphyses (for growth promotion indication), Acromegaly, Acute critical illness (post-surgery, trauma, respiratory failure), Pregnancy, Diabetic retinopathy, Uncontrolled Diabetes Mellitus, Active proliferative or severe non-proliferative diabetic retinopathy, Severe acute critical illness, Prader-Willi syndrome with severe obesity or respiratory impairment, Hypersensitivity to somatropin or excipients. Consult a qualified clinician before use.